<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638963</url>
  </required_header>
  <id_info>
    <org_study_id>P05225</org_study_id>
    <secondary_id>2007-005491-14</secondary_id>
    <nct_id>NCT00638963</nct_id>
  </id_info>
  <brief_title>Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)</brief_title>
  <acronym>STOP</acronym>
  <official_title>Temozolomide in Metastatic Breast Cancer Patients at High Risk of Brain Recurrence: Impact on the Incidence of Brain Metastases (STOP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether temozolomide can be used as a prophylaxis
      against brain recurrence in participants with metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the second most common cause of brain metastases. Overall survival after the
      development of brain metastases tends to be poor (6-8 months). Over-expression of Human
      Epidermal Growth Factor Receptor 2 (HER-2/neu), negative estrogen receptor, and young age at
      diagnosis seem to be indicators of high risk for brain metastases. Temozolomide may be a good
      candidate for prophylactic chemotherapy because of its ability to cross the
      blood-brain-barrier, achieving high concentrations in the central nervous system (CNS).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to poor accrual
  </why_stopped>
  <start_date type="Actual">October 2, 2008</start_date>
  <completion_date type="Actual">June 30, 2010</completion_date>
  <primary_completion_date type="Actual">June 30, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Recurrence of Brain Metastases</measure>
    <time_frame>1 Year</time_frame>
    <description>The analysis could not be performed due to low enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Progression-free Survival (PFS)</measure>
    <time_frame>24, 38, and 52 weeks</time_frame>
    <description>PFS was defined as the time interval from randomization to objective tumor progression or death from any cause.
The analysis could not be performed due to low enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Disease-free Survival (DFS)</measure>
    <time_frame>24, 38, and 52 weeks</time_frame>
    <description>DFS was defined as the time interval from randomization to any relapse (loco-regional, contra-lateral, and/or distant).
The analysis could not be performed due to low enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Distant Disease-free Survival (DDFS)</measure>
    <time_frame>24, 38, and 52 weeks</time_frame>
    <description>DDFS was defined as the time interval from randomization to only distant metastases (for example, bone, visceral organ, brain).
The analysis could not be performed due to low enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Brain Recurrence-free Survival (BRFS)</measure>
    <time_frame>24,38, and 52 weeks</time_frame>
    <description>BRFS was defined as the time interval from randomization to the appearance of brain metastases.
The analysis could not be performed due to low enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days on Temozolomide Treatment</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Temozolomide Taken</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had at Least One Dose Reduction During Treatment</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had at Least One Treatment Omission During Treatment</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Completed the Third Cycle of Treatment</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Neoplasm</condition>
  <condition>Brain Neoplasm</condition>
  <condition>Second Neoplasm</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
    <arm_group_label>Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of metastatic breast cancer.

          -  Participants must have completed first line of metastatic chemotherapy and have
             achieved complete or partial response or disease stability for at least 6 months from
             the first confirmation of disease stabilization.

          -  No clinical sign of brain progression.

          -  At least one of the following 3 conditions: HER2 +++, Young age (&lt; 50 years), and/or
             estrogen receptor (ER)-/progesterone receptor (PgR)-

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

          -  Life expectancy ≥3 months.

          -  Neutrophils ≥1.5 x 10^9/L, platelets ≥100 x 10^9/L, hemoglobin ≥9 g/dL, lymphocytes ≥1
             x 10^9/L.

          -  Bilirubin level either normal or &lt;1.5 x ULN (upper limit of normal).

          -  AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤2.5 x ULN (≤5 x
             ULN if liver metastases are present).

          -  Serum creatine &lt;1.5 x ULN.

          -  Effective contraception if the risk of conception exists.

        Exclusion Criteria:

          -  Concurrent chronic systemic immune therapy not indicated in the study protocol.

          -  Any investigational agent(s) within 4 weeks prior to entry.

          -  Participants that have completed 2nd, 3rd, or 4th line metastatic chemotherapy or
             participant in active chemotherapy treatment.

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction
             within the last 12 months.

          -  Acute or sub acute intestinal occlusion or history of inflammatory bowel disease.

          -  Known Grade 3 or Grade 4 allergic reaction to any of the components of the treatment.

          -  Known drug abuse/alcohol abuse.

          -  Legal incapacity or limited legal capacity.

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the participant to complete the study or sign meaningful informed consent.

          -  Women who are pregnant or breastfeeding.

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix (participants with a previous malignancy but without evidence of disease
             for ≥5 years will be allowed to enter the trial).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <results_first_submitted>June 23, 2011</results_first_submitted>
  <results_first_submitted_qc>June 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2011</results_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Temozolomide</title>
          <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
        </group>
        <group group_id="P2">
          <title>Observational</title>
          <description>No temozolomide treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">Received randomized treatment assignment</participants>
                <participants group_id="P2" count="3">Received randomized treatment assignment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">including follow-up at Week 38 &amp; Week 52</participants>
                <participants group_id="P2" count="3">including follow-up at Week 38 &amp; Week 52</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide</title>
          <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
        </group>
        <group group_id="B2">
          <title>Observational</title>
          <description>No temozolomide treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Recurrence of Brain Metastases</title>
        <description>The analysis could not be performed due to low enrollment.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Observational</title>
            <description>No temozolomide treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Recurrence of Brain Metastases</title>
          <description>The analysis could not be performed due to low enrollment.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Progression-free Survival (PFS)</title>
        <description>PFS was defined as the time interval from randomization to objective tumor progression or death from any cause.
The analysis could not be performed due to low enrollment.</description>
        <time_frame>24, 38, and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Observational</title>
            <description>No temozolomide treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Progression-free Survival (PFS)</title>
          <description>PFS was defined as the time interval from randomization to objective tumor progression or death from any cause.
The analysis could not be performed due to low enrollment.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Disease-free Survival (DFS)</title>
        <description>DFS was defined as the time interval from randomization to any relapse (loco-regional, contra-lateral, and/or distant).
The analysis could not be performed due to low enrollment.</description>
        <time_frame>24, 38, and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Observational</title>
            <description>No temozolomide treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Disease-free Survival (DFS)</title>
          <description>DFS was defined as the time interval from randomization to any relapse (loco-regional, contra-lateral, and/or distant).
The analysis could not be performed due to low enrollment.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Distant Disease-free Survival (DDFS)</title>
        <description>DDFS was defined as the time interval from randomization to only distant metastases (for example, bone, visceral organ, brain).
The analysis could not be performed due to low enrollment.</description>
        <time_frame>24, 38, and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Observational</title>
            <description>No temozolomide treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Distant Disease-free Survival (DDFS)</title>
          <description>DDFS was defined as the time interval from randomization to only distant metastases (for example, bone, visceral organ, brain).
The analysis could not be performed due to low enrollment.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Brain Recurrence-free Survival (BRFS)</title>
        <description>BRFS was defined as the time interval from randomization to the appearance of brain metastases.
The analysis could not be performed due to low enrollment.</description>
        <time_frame>24,38, and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
          <group group_id="O2">
            <title>Observational</title>
            <description>No temozolomide treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Brain Recurrence-free Survival (BRFS)</title>
          <description>BRFS was defined as the time interval from randomization to the appearance of brain metastases.
The analysis could not be performed due to low enrollment.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days on Temozolomide Treatment</title>
        <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days on Temozolomide Treatment</title>
          <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="65.82" lower_limit="1" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of Temozolomide Taken</title>
        <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Temozolomide Taken</title>
          <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
          <units>Milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9791.9" spread="8732.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had at Least One Dose Reduction During Treatment</title>
        <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had at Least One Dose Reduction During Treatment</title>
          <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had at Least One Treatment Omission During Treatment</title>
        <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had at Least One Treatment Omission During Treatment</title>
          <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Completed the Third Cycle of Treatment</title>
        <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Completed the Third Cycle of Treatment</title>
          <description>This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide</title>
          <description>Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles</description>
        </group>
        <group group_id="E2">
          <title>Observational</title>
          <description>No temozolomide treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator (PI) agrees not to publish or publicly present any interim results of the Study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication in accordance with provisions of laws related to protection of sensitive personal data and patentability of inventions.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary outcome measure and the survival analyses could not be analyzed due to the low enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

